January 4, 2017 / 11:39 PM / 9 months ago

BUZZ-Aeterna Zentaris Inc: Experimental test fails late-stage study

** Canadian drug developer’s U.S.-listed shares plunge 39.7 pct to $2.20 after hours

** Experimental test to diagnose adult growth hormone deficiency (AGHD) fails late-stage study

** Evaluating whether to continue with development of the test, macrilen

** To redirect resources to complete late-stage study of its cancer drug, Zoptrex

** AGHD is a medical condition in which the body does not produce enough growth hormone due to faulty pituitary gland

** Stock had lost nearly one-fifth of its value in 2016

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below